leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals studies on Ifenprodil begins with patients on two fronts

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has started work with patients on two different application for the repurposed drug Ifenprodil. Moreau telling Proactive how the studies will be conducted for use on IPF and chronic cough and also for the second use for treatment with COVID-19.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.31 CAD

CSE:AGN
Market: CSE
Market Cap: $34.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll...

Algernon Pharmaceutical (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has now enrolled a third of their patients in the Phase 2B/3 study of their repurposed drug Ifenprodil. Moreau discusses hitting that mark and also...

2 weeks, 2 days ago

2 min read